The Josep Carreras Foundation and Hospital Clinic in Barcelona sign a cooperation agreement to boost clinical research
The Josep Carreras Foundation will contribute €1,000,000 to Hospital Clinic to renovate and enlarge the Haemato-oncologic Clinical Trial Unit at Hospital Clinic in Barcelona.
This agreement opens the door to collaborations between scientists at the Josep Carreras Leukaemia Research Institute and the doctors and clinical researchers from Hospital Clinic in Barcelona carrying outclinical, translational and basic research.
Despite the progress over the last few years, we still lose two in every ten children and half the adult patients. Better results for new treatments depend on transferring results from basic clinical research to clinical practice.
Both the Josep Carreras Leukaemia Foundation and the Hospital Clinic in Barcelona are firmly resolved to jointly encourage scientific research, teaching and training in the field of leukaemia and other haematological malignancies.
In order to progress in these fields, a working partywas created with representatives from theHospital Clinic, the Josep Carreras Leukaemia Foundation and the Institute who have worked tirelessly to make this cooperation agreement a reality. The document was signed by Mr Josep Carreras, President of the Josep Carreras Leukaemia Foundation and Dr Josep Mª Piqué, General Director at the Clinic.
One of the first actions taken by the Josep Carreras Leukaemia Foundation to support clinical haematology was the funding of the transplant unit at Hospital Clinic in Barcelona back in 1989. With this new cooperation agreement the complete remodelling of the clinical trial unit will be possible, which will benefit both blood disease patients and those suffering from other tumours,asit will allow the number and scope of clinical trials in these fields to increase.
New discoveries around the genetic and metabolic alterations responsible for the growth and expansion of tumours make it possible to find drugs thatdistinguish between healthy blood cells and cancerous or leukaemic ones. In recent years a great number of drugs have been suggested as candidates toselectively attack the malignant cells while leaving healthy ones intact. These new drugs, which block the different metabolic pathways, must be tested quickly as they might be efficient treatments for patients who are not responding to the current ones. These clinical trials must take place in spacious and adequatelyequipped facilities that protect the dignity of patientsandthey must beapproved by hospitalethics committees.
“More and more, suitable treatment for patients with cancer is determined by the genetic profile of tumours, which represents a radical change in the strategy for dealing with this type of disease”, Dr Álvaro UrbanoIspizua, Director of the Oncology and Haematology Institute at the Clinic, points out. The success of new treatments is based on the transfer of biomedical research results to clinical practice. “This agreement signed today by the Josep Carreras Leukaemia Foundation and the Clinic, will allow progress in the field of new drugs to reach society a lot faster”, he adds.